Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD J CRANE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558301267
CMS profile
206564
Location
FAIRFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$26,257.14

96 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD J CRANE

NPI 1558301267 · CMS profile ID 206564

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FAIRFIELD, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558301267?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD J CRANE, NPI 1558301267, CMS profile ID 206564. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558301267?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EDWARD J CRANE, NPI 1558301267, CMS profile ID 206564. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558301267?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EDWARD J CRANE, NPI 1558301267, CMS profile ID 206564, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1558301267?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

96 matching records · $26,257.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 96 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–96 of 96.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $16.8207/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141560924 CMS
Immunocore Limited $23.4206/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103097383 CMS
EMD Serono, Inc. $38.0805/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120243049 CMS
Deciphera Pharmaceuticals Inc. $17.6705/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145872805 CMS
ABBVIE INC. $26.4305/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103512926 CMS
Secura Bio, Inc. $15.5405/20/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1133336343 CMS
ABBVIE INC. $17.4305/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103512924 CMS
ABBVIE INC. $10.0005/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103512922 CMS
Novartis Pharmaceuticals Corporation $19.5805/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086698197 CMS
AstraZeneca Pharmaceuticals LP $18.9505/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104755238 CMS
AstraZeneca Pharmaceuticals LP $24.3504/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105750913 CMS
PFIZER INC. $4.4504/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131305724 CMS
Celgene Corporation $23.8504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149553 CMS
Celgene Corporation $23.8504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149555 CMS
PFIZER INC. $10.4204/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131822276 CMS
Alexion Pharmaceuticals, Inc. $18.6004/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093982701 CMS
SpringWorks Therapeutics, Inc. $20.2504/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085803686 CMS
PFIZER INC. $14.6204/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131381772 CMS
SOBI, INC $14.4604/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141419100 CMS
Novartis Pharmaceuticals Corporation $18.4604/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086698187 CMS
Daiichi Sankyo Inc. $214.4003/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089411576 CMS
Celgene Corporation $18.9403/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149539 CMS
E.R. Squibb & Sons, L.L.C. $2,195.0003/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101516059 CMS
Daiichi Sankyo Inc. $5,500.0003/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089411574 CMS
Daiichi Sankyo Inc. $89.6003/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089411572 CMS
E.R. Squibb & Sons, L.L.C. $300.0003/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101516174 CMS
Lilly USA, LLC $16.6903/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136166822 CMS
E.R. Squibb & Sons, L.L.C. $124.5203/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101516063 CMS
GENZYME CORPORATION $19.4702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139815835 CMS
GlaxoSmithKline, LLC. $19.0702/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115851568 CMS
Janssen Biotech, Inc. $14.6802/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078503870 CMS
PFIZER INC. $10.9802/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131281156 CMS
ABBVIE INC. $13.1602/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103512918 CMS
ABBVIE INC. $1.0002/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103512920 CMS
PFIZER INC. $11.3702/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131281160 CMS
Daiichi Sankyo Inc. $23.0302/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089411578 CMS
E.R. Squibb & Sons, L.L.C. $13.3301/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101516039 CMS
GlaxoSmithKline, LLC. $20.8201/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115967310 CMS
AstraZeneca Pharmaceuticals LP $600.0001/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104422917 CMS
Novartis Pharmaceuticals Corporation $23.2901/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086698185 CMS
Aveo Pharmaceuticals, Inc. $16.0501/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143476968 CMS
PFIZER INC. $20.1601/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131102239 CMS
ARRAY BIOPHARMA INC $15.7701/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131102058 CMS
PFIZER INC. $16.5901/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131124872 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.0001/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086240110 CMS
Stemline Therapeutics Inc. $17.1201/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142959554 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $38,063.68 40
PY2020 $10,822.20 16
PY2021 $44,613.93 35
PY2022 $20,326.31 46
PY2023 $17,523.75 88
PY2024 $26,257.14 96
PY2025 $23,913.00 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $156.00 24
PY2024 Principal investigator $10,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560362
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560364
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560366
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560368
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560370
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560372
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560374
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560376
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560378
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560380
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560382
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560384
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560386
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560388
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560390
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560392
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560394
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560396
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560398
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560400
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560402
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560404
Principal investigator 1 Eisai Inc. $9.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560406
Principal investigator 1 Eisai Inc. $4.00 04/15/2025 Non-covered Recipient Entity
Oncology Hematology Care Inc
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 1244560408